LEMAITRE VASCULAR, INC.
In the published model solve dated 2026-Q2, anchored at $80.45, LEMAITRE VASCULAR, INC. (LMAT) is priced for +18.6% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 29, 2026 from SEC EDGAR filings.
• LeMaitre is a niche vascular-device maker that wins by selling unglamorous products the giants ignore: grafts, valvulotomes, and carotid shunts each posted record sales in Q1 2026, and gross margin reached 72.7%, up 350 basis points on pricing and manufacturing gains [Source: Q1 2026 earnings release]. • The price is the main risk, not the business: only the forward-growth lens reaches today's quote, so an investor is paying for roughly 23% annual operating-income growth to persist against a c
Is LMAT overvalued? See what's priced in →
329 institutional managers reported holding LMAT in 13F filings for the quarter ended 2026-03-31. 65 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 1.3M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (4.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
LMAT's share count grew 10.6% over the past five years even with $6.21M spent on repurchases. It pays a dividend, and has paid one every year in our records (15 and counting), raised 14 years straight; the current rate is $0.80 a share annually. Cash returned over the past three years: $44.43M in dividends and $4.67M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at LMAT over the trailing three years. Absence is a fact about the company, not a signal. 10 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
LMAT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | +2.3% | -10.5% |
| 2023-11-08 | -4.0% | +13.3% |
| 2024-03-01 | +15.2% | +9.9% |
| 2024-05-11 | +11.1% | +13.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
LMAT's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-06-05 (items 5.07); 2026-05-05 (items 2.02, 9.01); 2026-04-14 (items 5.02, 8.01); 2026-02-25 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 29, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.